Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ANDROGEN SUPPRESSIVE EFFECT OF GNRH AGONIST IN OVARIAN HYPERTHECOSIS AND VIRILIZING TUMORS
Autore:
PASCALE MM; PUGEAT M; ROBERTS M; ROUSSET H; DECHAUD H; DUTRIEUXBERGER N; TOURNIAIRE J;
Indirizzi:
HOP ANTIQUAILLE,CLIN ENDOCRINOL LAB,1 RUE ANTIQUAILLE F-69321 LYON 05FRANCE HOP ANTIQUAILLE,CLIN ENDOCRINOL LAB F-69321 LYON 05 FRANCE HOSP CIVILS LYON LYON FRANCE HOP ANTIQUAILLE,CENT BIOCHIM LAB F-69321 LYON 05 FRANCE HOP ANTIQUAILLE,ANAT & PATHOL LAB F-69321 LYON 05 FRANCE HOP DEBROUSSE,INSERM,U329 F-69321 LYON FRANCE HOP NORD ST ETIENNE F-42000 ST ETIENNE FRANCE HOP CHAMBERY F-73000 CHAMBERY FRANCE
Titolo Testata:
Clinical endocrinology
fascicolo: 5, volume: 41, anno: 1994,
pagine: 571 - 576
SICI:
0300-0664(1994)41:5<571:ASEOGA>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
HORMONE-RELEASING HORMONE; GRANULOSA-CELL TUMOR; TESTOSTERONE SECRETION; CHORIONIC-GONADOTROPIN; HYPERANDROGENISM; VIRILIZATION; LOCALIZATION; INHIBITION; RECEPTORS; HIRSUTISM;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
33
Recensione:
Indirizzi per estratti:
Citazione:
M.M. Pascale et al., "ANDROGEN SUPPRESSIVE EFFECT OF GNRH AGONIST IN OVARIAN HYPERTHECOSIS AND VIRILIZING TUMORS", Clinical endocrinology, 41(5), 1994, pp. 571-576

Abstract

OBJECTIVE Recent studies have suggested that androgen secretion by ovarian virilizing tumours may be gonadotrophin dependent. The aim of this study was to investigate the suppressive effect of GnRH agonist administration on androgen secretion in women with such tumours. DESIGN AND PATIENTS A single i.m. injection of D-Trp-6-GnRH (GnRHa), 3-75 mg, was given to five unrelated patients referred for clinical symptoms ofvirilization with plasma testosterone (T) levels greater than 7 nmol/l but with normal dehydroepiandrosterone sulphate (DHEAS) levels. Diagnoses of adrenal tumour or a nonclassical 21-hydroxylase deficiency were screened for by the dexamethasone suppression test, ACTH stimulation test and adrenal CT scanning, and were ruled out in all patients. The one premenopausal patient received cyproterone acetate in a dose of 50 mg twice daily for 3 weeks, starting 1 week before GnRHa administration. MEASUREMENT Testosterone, androstenedione (A), DHEAS, 17-hydroxyprogesterone (OHP), LH and FSH plasma concentrations were measured by radioimmunoassay of blood samples taken before and 3 weeks after GnRHa. RESULTS In each patient, GnRHa suppressed gonadotrophin levels and reduced T and A to the range for normal control women. With these results, and because accurate localization of an ovarian androgen secretingtumour could not be achieved by pelvic ultrasonography and CT scanning, exploratory laparotomy was undertaken. A Sertoli-Leydig cell tumourwas found in the premenopausal patient, and granulosa cell tumour, hilus cell tumour and two hyperthecoses in the four post-menopausal patients. After bilateral ovariectomy and hysterectomy in the post-menopausal woman and after unilateral ovariectomy in the premenopausal women,androgen levels were normalized. CONCLUSIONS In virilized women, the findings of increased serum testosterone with normal gonadotrophin levels and GnRHa suppression of gonadotrophins leading to normalization of testosterone levels, suggest that various ovarian androgen-secretingtumours, as well as hyperthecosis, are not autonomous but apparently depend upon continuous gonadotrophin stimulation.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/09/20 alle ore 06:22:28